The Oncology Institute ($NASDAQ:TOI) announced its earnings for the second quarter of FY2023 on August 9 2023, as of June 30 2023. Revenue for the quarter amounted to USD 80.2 million, a 31.7% rise year-on-year from the same period of the previous year. Net income was reported at USD -16.9 million, down from -5.4 million in the prior year.
The stock opened at $0.9 and closed at $1.0, down by 2.0% from the previous closing price of $1.0. This marks a significant increase in the company’s earnings from the same period last year, pointing to a successful quarter for the business. The success of ONCOLOGY INSTITUTE can be attributed to their innovative approach to cancer treatment and research, as well as their commitment to providing quality care for their patients. The company has invested heavily in research and development to create new treatments and therapies that can more effectively manage cancer and improve patient outcomes.
In addition, ONCOLOGY INSTITUTE’s team of dedicated professionals are passionate about providing the best possible care for their patients, leading to improved clinical outcomes. As a result of their impressive performance this quarter, ONCOLOGY INSTITUTE’s stock opened at a strong rate and maintained its value over the course of the day. This indicates that investors are confident in the company’s future prospects and are willing to invest in the company’s success. This confidence is reflected in the company’s financial performance, as they are able to further invest in new treatments and technologies to improve patient care. With the continued support of its investors, the company is well positioned for further success in the years ahead. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Oncology Institute. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Oncology Institute. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Oncology Institute. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Oncology Institute are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Oncology Institute Intrinsic Value
At GoodWhale, we recently conducted an analysis of the wellbeing of ONCOLOGY INSTITUTE. After taking into account various indicators, our proprietary Valuation Line determined that the fair value of an ONCOLOGY INSTITUTE share should be around $9.0. Unfortunately, we currently observe that the ONCOLOGY INSTITUTE stock is being traded at only $1.0, meaning it is undervalued by 88.9%. This discrepancy between the fair value and current trading price of ONCOLOGY INSTITUTE stock presents an excellent investment opportunity. More…
Risk Rating Analysis
Star Chart Analysis
Its competitors are Renalytix PLC, Synaptogenix Inc, Biodesix Inc.
Renalytix PLC, a kidney disease diagnostic company, has a market capitalization of 54.3 million as of 2022. The company’s Return on Equity is -91.92%. Renalytix PLC develops and commercializes kidney disease diagnostic products based on artificial intelligence. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Synaptogenix Inc is a clinical stage biotechnology company focused on the development of drugs to treat cognitive disorders. The company’s lead product candidate is SYN-120, a small molecule that is in Phase II clinical trials for the treatment of Alzheimer’s disease. Synaptogenix’s market cap is $48.23M and its ROE is -38.9%.
Biodesix, Inc. is a commercial-stage diagnostics company developing and commercializing blood tests for the early detection, diagnosis and guidance of treatment for cancer and other serious diseases. The company’s first product, the VeriStrat test, is a proteomic blood test used to predict how a patient will respond to standard of care non-small cell lung cancer treatments. The company’s second product, the Nodify Lung test, is a proteomic blood test used to diagnose lung cancer. The company’s third product, the Nodify XL2 test, is a proteomic blood test used to guide the treatment of patients with diffuse large B-cell lymphoma. Biodesix is also developing blood tests for the early detection and diagnosis of other cancers, including ovarian, colorectal and pancreatic cancers.
Oncoloy Institute’s second quarter (Q2) of FY2023 has earned a total revenue of USD 80.2 million, representing a 31.7% increase from the prior year. Despite the negative net income, investors should pay close attention to the strong revenue growth and take this as indication of the company’s potential for future success. Further analysis of Oncology Institute‘s operational performance, such as utilization of efficiency and cost control, is needed to provide a better understanding for investors.